Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Meetings Sponsor Program

The European Hematology Association (EHA) is a membership organization serving clinicians and researchers with an active interest in hematology in Europe and beyond. We bring together relevant stakeholders to promote excellence in patient care through education, research, and advocacy.

Read more

Abstract & Clinical Case Submission

Abstract submission is an important part of the 7th European CAR T-cell Meeting.

Read more

IMI2 Call for Research Proposals

The indicative budget for this topic is 40 million Euro, half of which by way of an in kind contribution from Industry Consortium EFPIA (European Federation of Pharmaceutical Industries and Associations) companies.

Read more

Proposal for an EU Regulation on Clinical Trials: A joint statement from non-commercial and commercial organisations

This statement outlines the areas of agreement within the health and research communities on where the Regulation will improve the research environment. Aspects of the Regulation that could be improved to further support clinical research are also highlighted.

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more